Sugi Predict

Sugi Predict / Compounds / SCHEMBL1330158

SCHEMBL1330158

SCHEMBL1330158

COC(=O)c1cc(Cl)ncc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.45
▸ LMNA P02545 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ KCNQ3 O43525 4/20 0.40
▸ KCNQ2 O43526 4/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ ASPH Q12797 1/20 0.40
▸ KDM8 Q8N371 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ GAA P10253 2/20 0.38
▸ JMJD6 Q6NYC1 1/20 0.38
▸ ATR Q13535 1/20 0.38
▸ ALPL P05186 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ TGFBR1 P36897 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KCNE1 P15382 2/20 0.37
▸ KCNQ1 P51787 2/20 0.37
▸ GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26598659 0.86 KDM4E (0.42) KDM4ELMNAMAPK1KCNQ3KCNQ2
SCHEMBL29416286 0.84 KDM4E (0.49) KDM4ELMNAMAPK1ABL1MAPT
SCHEMBL977733 0.84 KDM4E (0.49) KDM4ELMNAMAPK1ABL1MAPT
SCHEMBL30217866 0.82 KDM4E (0.47) KDM4ELMNAMAPK1ABL1MAPT
SCHEMBL236107 0.82 KDM4E (0.47) KDM4ELMNAMAPK1ABL1MAPT
SCHEMBL21530434 0.82 JMJD6 (0.56) KDM4EMAPTJMJD6TSHRALDH1A1
SCHEMBL2022063 0.81 KDM4E (0.42) KDM4EKCNQ3KCNQ2ASPHKDM8
SCHEMBL22321497 0.81 CA12 (0.49) KDM4ELMNAMAPK1ABL1GAA
SCHEMBL18725404 0.81 KDM4E (0.46) KDM4ELMNAMAPK1KCNQ3KCNQ2
SCHEMBL1809928 0.80 KDM4E (0.43) KDM4EMAPK1KCNQ3KCNQ2ASPH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 — — US disclosed
EP-4554938-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 — — EP disclosed
CN-119894879-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-25 — — CN disclosed
WO-2024015497-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2024-01-18 — — WO disclosed
CN-106573915-B Compounds active against bromodomains 纽韦卢森公司 2020-12-25 — — CN disclosed
US-10752640-B2 Compounds active towards bromodomains NUEVOLUTION A/S (DK) 2020-08-25 — — US disclosed
US-10752640-B2 Compounds active towards bromodomains NUEVOLUTION A/S (DK) 2020-08-25 — — US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 — — US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 — — US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 — — US disclosed
US-8426453-B2 Treatment of a stomach or small intestine ulcer with 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid ASTELLAS PHARMA INC. (JP) 2013-04-23 — — US disclosed
EP-1992361-B1 Remedy or preventive for digestive ulcer ASTELLAS PHARMA INC (JP) 2012-05-02 — — EP disclosed
US-8067446-B2 Methods for treating an ulcer of the small intestine and stomach ASTELLAS PHARMA INC. (JP) 2011-11-29 — — US disclosed
US-20110281919-A1 AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER ASTELLAS PHARMA INC. (JP) 2011-11-17 — — US disclosed
US-7820700-B2 2-phenylpyridine derivative ASTELLAS PHARMA INC. (JP) 2010-10-26 — — US disclosed
EP-1783116-B1 2-PHENYLPYRIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2009-08-26 — — EP disclosed
US-20090036428-A1 AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER ASTELLAS PHARMA INC. (JP) 2009-02-05 — — US disclosed
EP-1992361-A1 REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER Astellas Pharma Inc. (JP) 2008-11-19 — — EP disclosed
US-20070275950-A1 2-Phenylpyridine Derivative ASTELLAS PHARMA INC. (JP) 2007-11-29 — — US disclosed
EP-1783116-A1 2-PHENYLPYRIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2007-05-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275950-A1 2-Phenylpyridine Derivative NLRP3, XDH, UACA KDM4E 739/4885LMNA 1904/4885MAPK1 428/4885
US-20090036428-A1 AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER XDH, PEPD, HPN KDM4E 4662/4885LMNA 4517/4885MAPK1 1967/4885
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS BRD4, BRD3, BRDT KDM4E 626/4885LMNA 1289/4885MAPK1 1683/4885
US-10752640-B2 Compounds active towards bromodomains BRD4, BRD3, BRDT KDM4E 626/4885LMNA 1289/4885MAPK1 1683/4885
US-20110281919-A1 AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER XDH, PEPD, HPN KDM4E 4662/4885LMNA 4517/4885MAPK1 1967/4885
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 KDM4E 1141/4885LMNA 4491/4885MAPK1 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.